Last reviewed · How we verify
pentoxyphylline (PTX)
Pentoxyphylline (PTX) is a methylxanthine derivative that acts as a phosphodiesterase inhibitor, increasing cyclic AMP levels and improving blood flow.
Pentoxyphylline (PTX) is a methylxanthine derivative that acts as a phosphodiesterase inhibitor, increasing cyclic AMP levels and improving blood flow. Used for Intermittent claudication, Cerebral vasospasm.
At a glance
| Generic name | pentoxyphylline (PTX) |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Phosphodiesterase inhibitor |
| Target | Phosphodiesterase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This mechanism is thought to contribute to its therapeutic effects in conditions characterized by impaired blood flow, such as intermittent claudication. By increasing cyclic AMP levels, PTX can also have anti-inflammatory effects and improve red blood cell deformability.
Approved indications
- Intermittent claudication
- Cerebral vasospasm
Common side effects
- Headache
- Nausea
- Dizziness
Key clinical trials
- Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation (PHASE2)
- PentoxIfylline and Tocopherol for the Treatment of Post-radiotherapy Fibrosis in Head and Neck Cancer Patients (PHASE1)
- RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine (PHASE2, PHASE3)
- Comparison of the Efficacy of Mesotherapy and Extracorporeal Shock Wave Therapy in Patients With Lateral Epicondylitis (NA)
- Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE) (PHASE2)
- Nephroprotective Effect of Pentoxifylline Against Cisplatin in Patients With Head and Neck Cancer (NA)
- Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose) (PHASE2)
- Pentoxifylline in Patients With Ulcerative Colitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pentoxyphylline (PTX) CI brief — competitive landscape report
- pentoxyphylline (PTX) updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI